Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $424.0 million.

  • 4D Molecular Therapeutics' Liabilities and Shareholders Equity fell 29.81% to $424.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 10.04%. This contributed to the annual value of $560.4 million for FY2024, which is 64.87% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $424.0 million for Q3 2025, which was down 10.48% from $473.6 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $629.9 million during Q1 2024, with a 5-year trough of $240.6 million in Q3 2021.
  • Its 3-year average for Liabilities and Shareholders Equity is $466.0 million, with a median of $473.6 million in 2025.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 158.13% in 2024, then declined by 29.81% in 2025.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Liabilities and Shareholders Equity stood at $353.5 million in 2021, then dropped by 25.92% to $261.8 million in 2022, then rose by 29.81% to $339.9 million in 2023, then surged by 64.87% to $560.4 million in 2024, then fell by 29.81% to $424.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $424.0 million in Q3 2025, compared to $473.6 million in Q2 2025 and $515.7 million in Q1 2025.